NCT00168571

Brief Summary

Few data exist on long-term persistence of measles antibodies after vaccination of West African infants. The data that do exist indicate that the antibody titres decline very rapidly. Our data would be the first to describe the persistence of measles antibodies after two doses of measles vaccine, and the study would allow us to identify unprotected children and offer them revaccination. Since persistence of measles antibodies is of crucial importance to measles control, the study will contribute significantly to the existing knowledge and might have important implications for future eradication programmes.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,960

participants targeted

Target at P75+ for phase_4

Timeline
Completed

Started Mar 2002

Longer than P75 for phase_4

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2002

Completed
3.5 years until next milestone

First Submitted

Initial submission to the registry

September 9, 2005

Completed
6 days until next milestone

First Posted

Study publicly available on registry

September 15, 2005

Completed
1.3 years until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2007

Completed
Last Updated

September 22, 2011

Status Verified

September 1, 2006

First QC Date

September 9, 2005

Last Update Submit

September 21, 2011

Conditions

Measles

Keywords

Measles vaccineMeaslesMeasles antibodiesImmunisationLow income countryGuinea-BissauBandim Health ProjectMeasles antibody level

Outcome Measures

Primary Outcomes (1)

  • Measles antibody level

Interventions

Measles vaccineBIOLOGICAL

Eligibility Criteria

Age6 Years - 10 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Bandim Health Project

Bissau, Apartado 861, 1004 Bissau Codex, Guinea-Bissau

Location

Related Links

MeSH Terms

Conditions

Measles

Interventions

Measles Vaccine

Condition Hierarchy (Ancestors)

Morbillivirus InfectionsParamyxoviridae InfectionsMononegavirales InfectionsRNA Virus InfectionsVirus DiseasesInfections

Intervention Hierarchy (Ancestors)

Viral VaccinesVaccinesBiological ProductsComplex Mixtures

Study Officials

  • PETER AABY, MSc, Dr Med

    Bandim Health Project

    STUDY DIRECTOR

  • MAY-LILL GARLY, PHD, DTM&H

    Bandim Health Project

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

September 9, 2005

First Posted

September 15, 2005

Study Start

March 1, 2002

Study Completion

January 1, 2007

Last Updated

September 22, 2011

Record last verified: 2006-09

Locations

GU(1)